– Xalud Therapeutics announced that it has raised $30m in a Series C financing.
– Xalud is developing novel non-viral gene therapies to treat pathologic inflammation.
– XT-150 is a locally injectable plasmid DNA gene therapy expressing IL-10v – a proprietary long-acting, modified variant of IL-10 with enhanced durability properties over the naturally occurring wild-type cytokine.

– Paradromics, an Austin, Texas-based developer of high data rate Brain Computer Interfaces (BCI), raised $20M in seed funding.
– The round was led by Prime Movers Lab with participation from Westcott Investment Group, Dolby Family Ventures, Synergy Ventures, Pureland Global Venture, IT-Farm, and Alpha Edison.
– As part of the investment from Prime Movers Lab, Partner Dr. Amy Kruse will be joining the Paradromics Board of Directors.

– Amylyx Pharmaceuticals, Inc. closed $135m in Series C financing.
– Viking Global Investors led the round with participation from Bain Capital Life Sciences, Perceptive Advisors, Rock Springs Capital, Woodline Partners, Marshall Wace, Tybourne Capital Management, Verition Fund Management, aMoon Fund and Falcon Edge.
– The company intends to use the funds for the clinical development and potential launch plans for lead product candidate AMX0035, for the potential treatment of ALS, and further research and development in other neurodegenerative diseases.

– Omniscient Neurotechnology (“o8t™”), a pioneering brain mapping technology company, announced the completion of an AUD 40 million Series B financing round.
– The funding was led by family offices and high-net worth individuals, including Hancock Prospecting’s Executive Chairman Mrs. Gina Rinehart, and prominent fund manager Will Vicars.
– Using innovations in medical imaging and machine learning, Omniscient builds applications capable of modelling and analyzing connectomes or brain networks which are formed by the electrical connections within an individual’s brain.
– This technology transforms complex brain data into clear insight for doctors, psychologists, neuroscientists and brain technology innovators to better treat neurological disorders and mental illnesses.

– Translated, an Italy and US-based company that pioneered the use of artificial intelligence to support professional translators, announces that the world-leading private investment house Ardian has invested $25 million, leading a $30 million investment round.
– Translated is an end-to-end translation platform that combines its renowned proprietary adaptive neural machine translation software ModernMT with its network of 200 000 engaged linguists.
– Over the last several years, the company has experienced a consistent 30 percent organic growth rate year-on-year.
– Thanks to this human-machine symbiosis, Translated offerings have been constantly improving. Today Translated can serve global tech platforms including Airbnb, Google and Uber as well as small and medium-sized businesses.

– Aiforia from Helsinki provides AI-based solutions for clinical and preclinical image analysis in pathology.
– The company raised €25.2M in Series B funding.
– The round was led by Epredia, a subsidiary of PHC Holdings Corporation, with participation from Aktia Nordic Micro Cap and existing shareholders.
– The new investment will be used to strengthen the company’s global presence for pharmaceutical companies as well as develop and release new platforms for the diagnosis of the most common cancers in the world.

– Akili Interactive, maker of EndeavorRx™, the first and only prescription video game treatment, announced $160M in combined equity and debt financing.
– Akili is a pioneer of a new class of medicine and treatments that are not only effective and clinically-validated but that deliver amazing experiences to patients.
– The Company’s flagship product made history in June 2020 when it received U.S. Food and Drug Administration (FDA) clearance.
– With the completion of the oversubscribed Series D financing, Akili will continue to push the boundaries of traditional medicine to deliver on the promise of digital therapeutics for patients.